Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Moves to give biosimilars nonproprietary names different from brand products are more than a wrangle about words—they could mean biosimilars arrive stillborn to the market.
There are many advantages to becoming a company advisor, but academics should think carefully about the legal and personal implications before accepting a seat on the board.
The current academic culture needs to change its mission, which is narrowly focused on training PhDs to be the next generation of academic tenure-track scientists.